Radetec Diagnostics offers an at-home rapid test for sexually transmitted infections (STIs) that provides near-PCR accuracy within 10 minutes. Leveraging quantum dot nanoparticles and validated molecular/serological assays, this discreet solution aims to increase screening rates and facilitate early detection.
Funding
$275.8K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Sexually transmitted infections (STIs) represent a significant public health challenge, with a high incidence of asymptomatic cases leading to delayed diagnosis and treatment. Embarrassment and inconvenience associated with traditional testing methods deter individuals from seeking timely screening, contributing to the spread of infections and potential long-term health consequences.
Solution
Radetec Diagnostics is developing a novel at-home STI rapid test designed for convenient, private use and rapid results. The platform leverages validated molecular and serological assays integrated with fluorescent quantum dot nanoparticles for enhanced sensitivity, approaching PCR-level accuracy. This approach aims to overcome the barriers of traditional testing by offering a discreet, user-friendly solution that can be readily available in pharmacies. The technology facilitates early detection and encourages increased screening rates, thereby mitigating the impact of STIs.
Target Audience
The primary target audience includes individuals seeking discreet and convenient STI testing, as well as pharmacies and healthcare providers looking to offer accessible point-of-care diagnostic solutions.
Features
- Quantum dot-enabled lateral flow assay (LFA) for high-sensitivity biomarker detection.
- Integration of validated molecular and serological assay principles.
- Near-PCR sensitivity achieved through fluorescent nanoparticle technology.
- Swab-based sample collection for ease of use and minimal invasiveness.
- Rapid result generation within 10 minutes of sample application.
- Potential for pharmacy-based distribution and at-home self-testing.
- Proprietary method for producing aqueous-stable quantum dots.
- Two-step antibody conjugation capability for broad biomarker detection.